LIVE - EPIC 2022 - Day Two

Adam Greenbaum, MD, joined Emory after serving at Henry Ford Heart and Vascular Institute in Detroit, Michigan for the past 19 years as Co-director of the Center for Structural Heart Disease, Director of the Cardiac Catheterization Laboratory and Director of the Interventional Fellowship Program. He has dedicated his career to patient care, clinical research and fellow and resident education. Dr. Greenbaum has received numerous patient care and teaching awards, and is recognized as a clinical expert in the field of structural heart disease. His breakthrough research surrounding structural heart problems and the minimally invasive techniques he developed as a result, gives patients new treatment options. And his novel transcatheter methods and approaches to valvular heart disease bring new hope to patients with no other options. He is board certified in general and interventional cardiology and is a Fellow of the American College of Cardiology, the American Heart Association and the Society for Cardiovascular Angiography and Interventions. Dr. Greenbaum graduated from the New York University School of Medicine in New York, NY. He completed his internal medicine training at the University of Michigan in Ann Arbor, MI and his general and interventional cardiology training at Duke University in Durham, NC.

Works at Montefiore Medical Center, New York, NY, US. Features in 40 videos on Wondr Medical. Azeem Latib generally speaks on Bioresorbable Vascular Scaffold (BVS), Drug Eluting Stents (DES), Intravascular Ultrasound (IVUS), Bifurcation, and Intracoronary Imaging.

Catalin Toma, MD, is an interventional cardiologist and is certified in cardiovascular disease and interventional cardiology by the American Board of Internal Medicine. He currently serves as director of interventional cardiology for the Heart and Vascular Institute and director of the Interventional Fellowship at UPMC. He is an assistant professor of medicine at the University of Pittsburgh School of Medicine. He received his medical degree from Grigore T. Popa University of Medicine and Pharmacy in Iasi, Romania. Following a post-doctoral fellowship at Johns Hopkins in Baltimore, he completed an internal medicine residency at St. Luke’s Roosevelt Hospital Center in New York City and a fellowship in cardiovascular disease and interventional cardiology at UPMC. Dr. Toma joined the UPMC Heart and Vascular Institute in 2007. He currently leads the Chronic Total Occlusion Program as well as the Pulmonary Vascular Interventional Program at UPMC Presbyterian Hospital. He is an integral part of the Structural Heart Program with interests in the aortic and tricuspid space. Additional interests include intracoronary imaging and mechanical circulatory support. Dr. Toma has had an extensive amount of publications and presentations over his career, has several invention patents, and serves as a clinical study leader at local and national levels.

A staff clinician, adult interventional cardiologist at National Heart Lung and Blood Institute at NIH. Features in 3 videos on Wondr Medical. Christopher G. Bruce generally speaks on Live Cases.

Director of Rescue the Heart Program, Director CTO, and Advanced Coronary Therapeutics, Morristown Medical Center Dimitrios Karmpaliotis, MD, PhD, FACC, FSCAI is Medical Director of the Cardiovascular Rescue and Recovery Program and the Advanced Coronary Therapeutics and Chronic Total Occlusions Program at Morristown Medical Center. Dr. Karmpaliotis was formerly at the Center for Interventional Vascular Therapy at Columbia University Medical Center, where he provided world-class care since 2014. He is a former associate professor of medicine at Columbia University Medical School and formerly served as director of the Chronic Total Occlusions, Complex and High-Risk Angioplasty Program at New York-Presbyterian/Columbia University Medical Center.

George S. Hanzel, MD has joined Emory Healthcare and Emory University School of Medicine as an Associate Professor of Medicine. He is certified by the American Board of Internal Medicine in Cardiovascular Diseases and Interventional Cardiology. A graduate of Georgetown University School of Medicine in Washington, D.C., Dr. Hanzel completed his internship at the National Naval Medical Center in Bethesda, Maryland, his residency at Walter Reed Army Medical Center and then his cardiology fellowship at the National Naval Medical Center. Dr. Hanzel then served in the United States Navy, Lieutenant Commander, as a staff cardiologist at the Great Lakes Naval Hospital from 1999 to 2002. He completed an interventional cardiology fellowship in June 2004 at Beaumont Hospital in Royal Oak, Michigan. Dr. Hanzel then joined the Beaumont Hospital Royal Oak cardiology faculty in 2004 serving as Director of the Cardiac Catheterization Laboratory, Director of Structural Heart Disease, and associate professor at Oakland University William Beaumont School of Medicine until 2020. Dr. Hanzel's clinical and research interests include transcatheter aortic valve replacement, transcatheter therapies for mitral and tricuspid valve disease, alcohol septal ablation, and septal closure. Dr. Hanzel is a member of the STS/ACC Transcatheter Valve Therapy Registry Steering Committee and the Society for Cardiovascular Angiography and Interventions Structural Heart Disease Council.

Gregg W. Stone, MD, FACC, MSCAI is an interventional cardiologist and Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine (Cardiology) and Professor of Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 120 national and international multicenter randomized trials (many of which have led to new device approval or indications in the US), has authored more than 2000 manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. With a 2018 H-factor of 152, Dr. Stone was recently listed in Nature Medicine as one of the most prolific authors in science. Dr. Stone's areas of expertise include interventional therapies of acute coronary syndromes, myocardial infarction and cardiogenic shock; drug-eluting stents and bioresorbable scaffolds; left main and complex coronary artery disease intervention; antiplatelet and antithrombotic pharmacotherapies; transcatheter valve repair and replacement; interventional hypertension and heart failure therapies; left atrial appendage closure; intravascular imaging (IVUS, OCT and NIRS); vulnerable plaque diagnosis and treatment; adjunctive interventional devices including atherectomy, distal embolic protection, thrombectomy, covered stents, chronic total occlusion devices, and brachytherapy; saphenous vein graft therapies; contrast nephropathy; clinical trial design; and regulatory issues. Dr. Stone is the director of TCT, the world's largest symposium devoted to interventional cardiology and vascular medicine. Dr. Stone founded the annual National Interventional Cardiology Fellow's Course and Transcatheter Valve Therapies TVT), the Chronic Total Occlusion (CTO) Summit, and co-directs multiple other meetings in the US, China, Russia, Europe, S. Korea and elsewhere.

Isida Byku, MD, FACC is an Assistant Professor of Medicine at Emory University, specializing in coronary and structural heart intervention. Dr. Byku also serves as the fellowship program director for the Structural Heart and Valve fellowship. After receiving her medical degree from Dartmouth Medical School, Dr. Byku completed residency training in internal medicine at the Johns Hopkins Hospital, followed by fellowship training in cardiovascular disease at the University of Chicago. She then came to Emory for a two-year fellowship in interventional cardiology and structural heart and valve disease, upon completion of which she joined as faculty. As a member of the cutting-edge structural team at Emory, Dr. Byku's areas of interest include advancements in the field of transcatheter therapies for structural heart and valve disease.

Dr. James Harvey, MD, FACC is an Interventional Cardiologist with WellSpan Health. He attended undergraduate and graduate school at Vanderbilt University and then went to medical school at the University of South Florida College of Medicine. Dr. Harvey then did his residency training in Internal Medicine at Emory University Hospital in Atlanta, GA and completed fellowship training in both Cardiovascular Medicine and Interventional Cardiology at the Cleveland Clinic in Cleveland, OH where he served as the chief interventional fellow. Board-certified in Cardiovascular Medicine and Interventional Cardiology, Dr. Harvey has a special interest in structural and valvular heart disease, complex coronary artery disease, and mechanical cardiovascular circulatory support. He is the Director of the Cardiac Catheterization Laboratory and the Structural Heart Program at WellSpan York Hospital. He also serves as a member of the Executive Council for the Pennsylvania Chapter of the American College of Cardiology.

A medical director, structural heart and valve team at Carilion Clinic. Features in 2 videos on Wondr Medical. Jason Forest generally speaks on Live Cases.

An internationally recognized interventional cardiologist, Dr. Moses has performed more than 15,000 interventional procedures, authored over 600 publications, and served as lead investigator for numerous national and international clinical studies that have demonstrated the effectiveness and safety of coronary stent placement. In 2002, Dr. Moses was the lead investigator on a large clinical trial, the first in the U.S. that demonstrated the enormous benefit that led to FDA approval of the first drug-coated stent now used in the majority of interventional procedures in the U.S. Most recently in on the Executive Committee of PARTNER trial; they brought the first transcatheter aortic valve to clinical use in the U.S. He currently serves as Director of Interventional Cardiovascular Therapeutics at Columbia University Medical Center and as Director of Advanced Cardiac Interventions at St Francis Hospital and Heart Center in Roslyn, NY. He is also a pioneer in developing approaches involving minimally invasive surgery, angioplasty, gene therapy, novel imaging technologies and various support devices that allow for wider application of interventional cardiovascular procedures.

Dr. Kevin J. Croce is an interventional cardiologist and the director of the Chronic Total Occlusion Complex Percutaneous Coronary Intervention Program at Brigham and Women’s Hospital (BWH). He is an assistant professor of medicine at Harvard Medical School (HMS) who also directs the BWH Translational Discovery Laboratory which is a centralized research facility that uses state-of-the-art technology to perform preclinical testing of promising therapies and medical devices. Dr. Croce received his medical and Ph.D. degrees from Tufts University School of Medicine. He completed an internal medicine residency, a cardiology fellowship and an interventional cardiology fellowship at BWH. Dr. Croce is board certified in internal medicine, cardiovascular disease and interventional cardiology. His clinical interests include advanced treatments for obstructive coronary artery disease (CAD), and optimization of antithrombotic and antiplatelet pharmacotherapy. The author of over 50 peer-reviewed publications, Dr. Croce’s research focuses on understanding the molecular pathobiology of atherothrombotic (CAD) and on identifying new targets for CAD treatment. His research has received support from the National Institutes of Health.

Dr. Reisman received his Medical Degree from Sackler School of Medicine, New York State Program. He did his Internship at Robert Wood Johnson Hospital in New Brunswick. He finished both Residency in Internal Medicine and Cardiology Fellowship at St. Luke’s Roosevelt Hospital in New York. Dr. Reisman completed Interventional Cardiology at University of California San Diego Medical Center in San Diego. Dr. Reisman has a very productive career as exemplified by authorship and co-authorship of over 100 publications. He is a highly regarded practitioner in the field of interventional cardiology and a leader in national education forum. Dr. Reisman serves as Director of Structural Heart Disease at Weill Cornell Medicine

Martin B. Leon, MD is Professor of Medicine at Columbia University Irving Medical Center (CUIMC). Dr. Leon is also Director of Columbia Interventional Cardiovascular Care, Director of the Cardiac Catheterization Laboratories, and is on the Executive Board of the Columbia Structural Heart & Valve Center. He is a practicing interventional cardiologist at NewYork-Presbyterian Hospital in New York City. Dr. Leon is also the Founder and Chairman Emeritus of the Cardiovascular Research Foundation. Dr. Leon has served as principal investigator for over 50 clinical trials that have helped shape the field of interventional cardiovascular medicine, including the following studies: STRESS, STARS, Gamma-one, SIRIUS, ENDEAVOR, and most recently, the PARTNER trial, studying the value of transcatheter valve therapy for patients with aortic stenosis. Dr. Leon has co-authored over 1550 publications, has performed over 10,000 interventional procedures, and has had a major impact as a thought-leader and innovator in the expanding sub-specialty of interventional cardiovascular device and drug therapies. He is the Director and Founder of Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier interventional cardiovascular meeting, which recently celebrated its 24th anniversary. Dr. Leon has also served as Director or Co-Director of more than 100 international educational programs in areas of interventional cardiology. Dr. Leon has received 10 international career achievement awards and was awarded an honorary degree from the University of Athens.

Nicholas J. Lembo, MD, is an interventional cardiologist affiliated with NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Howard University College of Medicine in Washington, DC. Dr. Lembo completed his internship and residency at Georgetown University Hospital in Washington, DC, a cardiology fellowship at the University of Texas Health Science Center in San Antonio, Texas and an interventional cardiology fellowship at the Andreas Gruentzig Cardiovascular Center, Emory University in Atlanta, Georgia.

Dr. Pratik Sandesara is an interventional cardiologist at Emory University Hospital and an assistant professor of medicine at Emory University School of Medicine. His clinical focus is on complex and high-risk percutaneous coronary intervention including chronic total occlusion revascularization.

Dr. Rhian E. Davies is currently practicing at WellSpan Health in York Pa. She completed her Internal Medicine Residency and General Cardiology Fellowship at Penn State Milton S. Hershey Medical Center in 2018. This w followed by an interventional year at Warren Alpert Medical School of Brown University. She subsequently completed an Advanced Interventional Cardiology Fellowship at the University of Washington where she focused on CTO PCI. Her clinical interest include radial access, mechanical circulatory support, complex coronary and CTO procedures.

Dr Stéphane Rinfret is an academic interventional cardiologist and world-renown expert in chronic total occlusion (CTO) percutaneous coronary intervention (PCI). He was appointed chief of interventional cardiology at the McGill University Health Centre (MUHC) and associate professor of medicine at McGill University in 2016 where he built a very active chronic total occlusion (CTO) and Complex Higher-risk but Indicated Procedures (CHIP) program. He has now moved to the US to work with at Emory Healthcare and Emory University, as associate-director of complex PCI and full professor (acting) of Medicine, to pursue his academic career and busy clinical practice, mostly at Emory Saint Joseph's Hospital, the oldest hospital of Atlanta serving a very large population. Dr Rinfret has held several peer-reviewed grants, published over 150 peer-reviewed articles, several abstracts, and has been invited over 300 times to give lectures in the last 10 years. His epidemiological research focuses on health services and outcomes. He is also a high-volume and world-renown coronary operator, performing over 400 percutaneous coronary interventions (PCIs) per year, mostly from the transradial approach and most with complex anatomies. Dr Rinfret was one of the Canadian pioneers in CTO PCI and has contributed to expand access to the technique in Canada and all around the world through sharing his expertise. He is the lead editor of a textbook on CTO PCI published by Springer in 2015, currently being reviewed for a second edition. He has performed over 1200 CTO PCIs since January 2010, one of the largest volumes in the world, including a large number of retrograde procedures, and pursues a very active teaching program of transradial and CTO PCI techniques in Canada and Europe.

Dr. Rogers is an interventional cardiologist and scientific lead for the MedStar Heart & Vascular Institute Structural Heart Disease program. He has a special interest in all aspects of minimally invasive treatment of structural heart disease, including Transcatheter Aortic Valve Replacement (TAVR), Transcaval access, Transcatheter Electrosurgery (LAMPOON and BASILICA techniques), para-valvular leak closure, percutaneous treatment of mitral valve regurgitation including Mitraclip and Transcatheter Mitral Valve Replacement (TMVR), LAA occluder, percutaneous pulmonary and tricuspid valve interventions, and cerebral protection devices for TAVR.

Vasilis Babaliaros, MD is Professor of Medicine and Surgery at Emory University School of Medicine, and Co-Director of the Emory Structural Heart and Valve Center. He received his bachelor of science in biomedical engineering, summa cum laude, from Duke University, and his medical degree, magna cum laude, from Emory University. He also completed his training in Internal Medicine, Cardiology and Interventional Cardiology at Emory University. He received advanced training in valvular intervention under the direction of Alain Cribier at the University of Rouen, France before returning to Emory to join the faculty. His research interests include percutaneous cardiac valve repair and replacement as well as treatment of structural and congenital heart disease.

Dr. William Nicholson is acting Associate Professor of Medicine at Emory University School of Medicine and Director of Complex Coronary and Cardiac Intervention at Emory Healthcare. Dr. Nicholson also serves as the program director for the Advanced Complex High-Risk Interventional Procedures (CHIP) fellowship at Emory University Hospital. Dr. Nicholson came to Emory in 2020 after fourteen years in private interventional cardiology practice in York, Pennsylvania. While in private practice, Dr. Nicholson founded and developed that institution’s carotid stenting program, structural heart program, transcatheter aortic valve replacement program, and the complex coronary intervention program. He also has become nationally and internationally recognized for his expertise in treatment of Chronic Total Occlusions (CTO’s). He is a perennial live case operator for nationally televised conferences. Dr. Nicholson formerly trained at Emory University Hospital having completed his general cardiology and interventional fellowship in 2006. He completed his medical residency at Brown University Hospitals where he also served as Chief Medical Resident. He is a graduate of Pennsylvania State College of Medicine.

Wissam A Jaber is professor of medicine, director of the cadiac cath lab at Emory University Hospital, and program director of the interventional cardiology fellowship. His clinical and research interests include CTO PCI and pulmonary embolism intervention. He trained at Duke University (Internal Medicine) and the Mayo Clinic (Cardiology) and has been in practice since 2008.

Ziad Ali is the Director of the DeMatteis Cardiovascular Institute, Director of Investigational Interventional Cardiology, and Director of Cardio-nephrology at St Francis Hospital & Heart Center in New York. He is also Director of the Angiographic Core Laboratory at Cardiovascular Research Foundation and Associate Professor of Medicine at Columbia University Medical Center. His clinical research interests focus on the use of intravascular imaging and physiology technologies such as optical coherence tomography, intravascular ultrasound, and flow wire assessment to optimize coronary interventions, for which he has served as a Global principal investigator on a number of trials. Dr. Ali is also a recognized innovator, playing an integral role in the development of the Resting Full-Cycle Ratio (RFR) and Shockwave intravascular lithotripsy. Clinically Dr. Ali developed pioneering techniques to perform vascular interventions without contrast administration, including IVUS-guided zero-contrast PCI and OCT using saline flush media, protecting patients with advanced kidney disease from acute kidney injury and the need for dialysis.